This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.


Disclosure: This post may contain affiliate links. This means, we may receive a small commission if you choose to purchase something from a link we post (including links to amazon.com because we are a participant in the Amazon Services LLC Associates Program. Don’t worry, it won’t cost you anything. This small percentage just helps us keep the power on and the Diet Coke stocked. We appreciate your support!
Fodor is more enthusiastic about the LipoSonix technology. "I am very optimistic," he says." I love the results," he says citing as much as a 7-centimeter reduction in waist circumference seen in clinical trials conducted in Mexico. This technology, which uses high-intensity ultrasound waves, beamed about an inch under the skin to break up fatty tissue, has been studied in both pig models and in 33 people in Mexico, he says. The company has applied for FDA status to begin preclinical studies in the U.S. and expects such trials to begin in 2007.

We use cookies to give you the best possible experience of our website. Some of the cookies we use identify your browsing habits and enable us to show you other content and products relevant to your interests. If you continue, we'll assume you're happy for your web browser to receive all cookies from our website. See our cookie policy for more information on cookies and how to manage them.
The “AXA PPP Group” for this purpose is AXA PPP healthcare Group Limited, its holding company and all subsidiaries of its holding company including (but not limited to) AXA PPP healthcare Limited, AXA ICAS Limited, AXA ICAS Occupational Health Services Limited, Health on Line Company UK Limited and AXA PPP healthcare Administration Services Limited.

1 July 2015: The CMA is considering whether it is or may be the case that this transaction has resulted in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation has resulted, or may be expected to result, in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.

×